A polymeric amine synergist is disclosed herein. An example of the polymeric amine synergist includes an aniline moiety, a polyethylene glycol chain, and an ether linkage attaching one end of the polyethylene glycol chain to the aniline moiety. The polymeric amine synergist may be included in a photo curable ink composition.

A polymeric amine synergist is disclosed herein. An example of the polymeric amine synergist includes an aniline moiety, a polyethylene glycol chain, and an ether linkage attaching one end of the polyethylene glycol chain to the aniline moiety. The polymeric amine synergist may be included in a photo curable ink composition.

A polymeric amine synergist is disclosed herein. An example of the polymeric amine synergist includes an aniline moiety, a polyethylene glycol chain, and an ether linkage attaching one end of the polyethylene glycol chain to the aniline moiety. The polymeric amine synergist may be included in a photo curable ink composition.

A polymeric amine synergist is disclosed herein. An example of the polymeric amine synergist includes an aniline moiety, a polyethylene glycol chain, and an ether linkage attaching one end of the polyethylene glycol chain to the aniline moiety. The polymeric amine synergist may be included in a photo curable ink composition.

The present disclosure is drawn to polymeric amine synergist compositions. The polymeric amine synergist composition can include a polymeric amine synergist including an aminobenzene modified with a polyether chain connecting to the aminobenzene through an ether linkage. The polymeric amine synergist can be present in a reaction product mixture with either i) an aminophenol, or ii) a carbonate base.

The present disclosure relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, for use in the treatment of cancers.

In one embodiment, the application discloses a composition for the reduction of an organic compound comprising a nitro group to form an organic compound comprising an amine group, the composition comprising: a) a transition metal salt; b) an iron salt; and c) a reducing agent; and methods for the use of such compositions, including Click chemistry and cross coupling reactions.

In one embodiment, the application discloses a composition for the reduction of an organic compound comprising a nitro group to form an organic compound comprising an amine group, the composition comprising: a) a transition metal salt; b) an iron salt; and c) a reducing agent; and methods for the use of such compositions, including Click chemistry and cross coupling reactions.

Parts of compounds, after being labeled by radionuclide, of the phenyl benzyl ether derivative, are used as A plaque imaging agent. The structural formula of the phenyl benzyl ether derivative is shown by formula (I). The present invention develops a kind of brand new phenyl benzyl ether derivative which has high affinity with A plaques in brains of AD patients. The chemical structure of the phenyl benzyl ether derivative is different from that of compounds disclosed in the prior art and the phenyl benzyl ether derivative belongs to a brand new compound for diagnosing and treating AD. The obtained A plaque imaging agent has the advantages that the in-vivo stability is good, the fat solubility is low, the removal speed for the brain is fast, the problem of removing the radionuclide in vivo does not exist, and the application prospect and the market value are great.

##STR00001##

Parts of compounds, after being labeled by radionuclide, of the phenyl benzyl ether derivative, are used as A plaque imaging agent. The structural formula of the phenyl benzyl ether derivative is shown by formula (I). The present invention develops a kind of brand new phenyl benzyl ether derivative which has high affinity with A plaques in brains of AD patients. The chemical structure of the phenyl benzyl ether derivative is different from that of compounds disclosed in the prior art and the phenyl benzyl ether derivative belongs to a brand new compound for diagnosing and treating AD. The obtained A plaque imaging agent has the advantages that the in-vivo stability is good, the fat solubility is low, the removal speed for the brain is fast, the problem of removing the radionuclide in vivo does not exist, and the application prospect and the market value are great.

##STR00001##